First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis
Reheman Adili(St. Michael's Hospital), Michael Holinstat(University of Michigan), Anton Simeonov(National Institutes of Health), Ajit Jadhav(National Institutes of Health), John C. Freedman(University of California, Santa Cruz), K. Mast(University of California, Santa Cruz), David J. Maloney(National Institutes of Health), Benjamin E. Tourdot(Cincinnati Children's Hospital Medical Center), Theodore R. Holman(University of California, Santa Cruz), Abigail Green(University of California, Santa Cruz), Jennifer Yeung, Diane K. Luci(University of California, Santa Cruz)
Cited by 112
Related Papers
Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|391
Erratum: Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|327
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance
|Cancer Cell|2018|255
Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry
|Cell Discovery|2018|194
KDM5 histone demethylases repress immune response via suppression of STING
|PLoS Biology|2018|166